(Total Views: 399)
Posted On: 09/10/2019 8:36:42 PM
Post# of 145903
It is going to be a very uncomfortable 2nd quarter earnings call for gild in 2020. By then Leronlimab will be on the market and all the analysts will be asking how gild completely missed this drug and why they have nothing to replace the biggest revenue generator they have. It is just shocking that gild is risking there future by letting this drug get this far.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)